Home
Abstract
My Abstract(s)
Login
ePosters
Back
Final Presentation Format
Podium Abstract
Eposter Presentation
Eposter in PDF Format
Accept format: PDF. The file size should not be more than 5MB
Eposter in Image Format
Accept format: PNG/JPG/WEBP. The file size should not be more than 2MB
Presentation Date / Time
Submission Status
Submitted
Abstract
Abstract Title
Comprehensive Bioinformatics Approach for Identifying Lipid-Related Markers in Bladder Cancer Prognosis
Presentation Type
Podium Abstract
Manuscript Type
Basic Research
Abstract Category *
Novel Advances: Other Urology Translational Studies
Author's Information
Number of Authors (including submitting/presenting author) *
8
No more than 10 authors can be listed (as per the Good Publication Practice (GPP) Guidelines).
Please ensure the authors are listed in the right order.
Country
Taiwan
Co-author 1
Yu-De Wang thomas1101111@gmail.com China medical university hospital urology Taichung City Taiwan *
Co-author 2
Chi-Ping Huang huangchiping@yahoo.com.tw China medical university hospital urology Taichung City Taiwan -
Co-author 3
Chia-Hsin Liu b881642@gmail.com China medical university graduate institute of biomedical sciences, school of medicine, college of medicine Taichung City Taiwan -
Co-author 4
Pei-Chun Shen y800418@gmail.com China medical university graduate institute of biomedical sciences, school of medicine, college of medicine Taichung City Taiwan -
Co-author 5
Hsiu-Cheng Liu hcliu0307@gmail.com China medical university graduate institute of biomedical sciences, school of medicine, college of medicine Taichung City Taiwan -
Co-author 6
Meng-Hsin Tsai tiff130820@gmail.com China medical university graduate institute of biomedical sciences, school of medicine, college of medicine Taichung City Taiwan -
Co-author 7
Yo-Liang Lai yolianglai@gmail.com China medical university hospital Radiology Taichung City Taiwan -
Co-author 8
Wei-Chung Cheng cwc0702@gmail.com China medical university graduate institute of biomedical sciences, school of medicine, college of medicine Taichung City Taiwan -
Co-author 9
Co-author 10
Co-author 11
Co-author 12
Co-author 13
Co-author 14
Co-author 15
Co-author 16
Co-author 17
Co-author 18
Co-author 19
Co-author 20
Abstract Content
Introduction
Bladder cancer (BLCA) remains a pressing global health challenge, characterized by high recurrence, progression, and mortality rates. Traditional prognostic tools, such as the TNM classification, show limited accuracy, particularly in the context of immune checkpoint inhibitors (ICI). In this study, we employed comprehensive bioinformatics analyses on the TCGA dataset to identify genes that are differentially expressed and methylated in BLCA.
Materials and Methods
We analyzed transcriptomic and methylation data from the TCGA BLCA cohort to identify differentially expressed and differentially methylated genes. By integrating both datasets, and using machine learning techniques were employed to generate a 25-gene survival signature, which was validated using independent cohorts, including the IMvigor 210 trial. Functional enrichment and KEGG pathway analyses were performed to elucidate the biological roles of the signature, and in vitro experiments confirmed the involvement of key lipid metabolism genes.
Results
Our analysis identified a 25-gene signature significantly associated with 5-years disease-specific survival (DSS) in BLCA patients(HR:2.3, p<0.001). Functional enrichment analysis highlighted key genes like FASN, SCD within this signature, emphasizing the critical involvement of lipid metabolism pathways, particularly those related to FASN and SCD. The prognostic value of this gene signature was validated across four independent cohorts, including the IMvigor 210 clinical trial dataset, consistently distinguishing high-risk from low-risk patients and correlating with survival outcomes across BLCA stages. In vitro experiments further demonstrated that inhibiting FASN and SCD impairs BLCA cell proliferation and migration, suggesting their potential as therapeutic targets.
Conclusions
This study introduces a novel biomarker for BLCA prognosis while shedding light on its underlying molecular mechanisms. The findings underscore the importance of this biomarker in the clinical epigenetics of BLCA and offer new avenues for personalized treatment strategies
Keywords
Urothelial Cancer, Novel Biomarkers, lipid
Figure 1
Figure 1 Caption
Figure 2
Figure 2 Caption
Figure 3
Figure 3 Caption
Figure 4
Figure 4 Caption
Figure 5
Figure 5 Caption
Character Count
1774
Vimeo Link
Presentation Details
Session
Free Paper Podium(03): Oncology Bladder UTUC (A)
Date
Aug. 14 (Thu.)
Time
16:42 - 16:48
Presentation Order
13